Two Cases of Thrombosis Caused by Ethinylestradiol and Cyproterone Acetate Tablets during Thrombocytopenia in Patients with Acute Myeloid Leukemia

doi:10.19803/j.1672-8629.20240892

Abstract

Abstract: Objective To explore the risk of thrombosis in female patients with acute myeloid leukemia (AML) who use combined oral contraceptives (COCs) during thrombocytopenia so as to provide a reference for safe use of COCs in such patients. Methods The clinical data of two AML patients who developed thrombosis after taking ethinylestradiol and cyproterone acetate tablets during thrombocytopenia was analyzed and the risk factors and monitoring measures for thrombosis in AML patients taking COCs were discussed. Results Thrombosis was correlated with COCs in both patients. After quick diagnosis and treatment, the prognosis was good. AML patients were often considered high-risk for bleeding due to low platelet counts, but they were also at high risk for thrombosis such as blood stasis and endothelial damage. When COCs were used, the risk of cerebral venous sinus thrombosis and deep vein thrombosis increased significantly. Conclusion Clinical pharmacists should be alert to the risk of thrombosis in AML patients using COCs. Coagulation indicators and symptoms of patients should be monitored to detect thrombosis early and reduce the risk.

Key words: Ethinylestradiol and Cyproterone Acetate Tablets, Oral Contraceptives, Acute Myeloid Leukemia, Thrombocytopenia, Thrombosis, Adverse Drug Reactions

CLC Number:

LI Shuyue, QIU Huiying, WU Jiaqi, GAO Junwei. Two Cases of Thrombosis Caused by Ethinylestradiol and Cyproterone Acetate Tablets during Thrombocytopenia in Patients with Acute Myeloid Leukemia[J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 1045-1048.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240892

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I9/1045

References

[1] VENUGOPAL S, SEKERES MA.Contemporary Management of Acute Myeloid Leukemia: a Review[J]. JAMA Oncology, 2024, 10(10): 1417-1425.
[2] BENTO L, CANARO M, BASTIDA JM, et al.Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Journal of Clinical Medicine, 2022, 11(5): 1364.
[3] MORIMONT L, HAGUET H, DOGNÉ JM, et al.Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk[J]. Front Endocrinol (Lausanne), 2021, 12: 769187.
[4] LAVASSEUR C, NEUKAM S, KARTIKA T, et al.Hormonal Therapies and Venous Thrombosis: Considerations for Prevention and Management[J]. Research and Practice in Thrombosis and Haemostasis, 2022, 6(6): e12763.
[5] DURMUȘ B, YPERZEELE L, ZUURBIER SM.Cerebral Venous Thrombosis in Women of Childbearing Age: Diagnosis, Treatment, and Prophylaxis during a Future Pregnancy[J]. Ther Adv Neurol Disord, 2020, 13: 1756286420945169.
[6] SKEITH L, BATES SM. Estrogen, Progestin,Beyond: Thrombotic Risk and Contraceptive Choices[J]. Hematology, 2024 (1): 644-651.
[7] HEIKINHEIMO O, TOFFOL E, PARTONEN T, et al.Systemic Hormonal Contraception and Risk of Venous Thromboembolism[J]. Acta Obstet Gynecol Scand, 2022, 101(8): 846-855.
[8] JODELE S, LASKIN BL, DANDOY CE, et al.A New Paradigm: Diagnosis and Management of HSCT-Associated Thrombotic Microangiopathy as Multi-System Endothelial Injury[J]. Blood Rev, 2015, 29(3): 191-204.
[9] FUKATSU M, IKEZOE T.Cancer-Associated Thrombosis in Hematologic Malignancies[J]. Int J Hematol. 2024, 119(5): 516-525.
[10] WINDISCH S, FRISHMAN WH.Thrombotic and Vascular Complications of Oral Contraceptives[J]. Cardiology in Review, 2024, 10: 1097.
[11] MEAIDI A, MASCOLO A, SESSA M, et al.Venous Thromboem-bolism with Use of Hormonal Contraception and Non-Steroidal Anti-Inflammatory Drugs: Nationwide Cohort Study[J]. BMJ, 2023, 382: e074450.
[12] TEKLE E, GELAW Y, ASRIE F.Hematological Profile Changes among Oral Contraceptive Users: a Narrative Review[J]. J Blood Med, 2022, 13: 525-536.
[13] DEBIEC KE, TODD N.Gynecologic Care for Pediatric and Adolescent Patients Undergoing Hematopoietic Stem Cell Transplantation[J]. J Pediatr Adolesc Gynecol, 2021, 34(2): 112-116.
[14] CHANG K, MERIDETH MA, STRATTON P.Hormone Use for Therapeutic Amenorrhea and Contraception during Hematopoietic Cell Transplantation[J]. Obstet Gynecol, 2015, 126(4): 779-784.
[15] DIX C, HUNT BJ.The Changing Face of Cerebral Venous Sinus Thrombosis-Emerging New Causes and Treatments[J]. Journal of Thrombosis and Haemostasis, 2024, 22(12): 3346-3354.
[16] SAPOSNIK G, BUSHNELL C, COUTINHO JM, et al.Diagnosis and Management of Cerebral Venous Thrombosis: a Scientific Statement from the American Heart Association[J]. Stroke, 2024, 55(3): e77-e90.
[17] BOUSSER MG, CRASSARD I. Cerebral Venous Thrombosis, Pregnancy and Oral Contraceptives[J]. Thromb Res, 2012, 130(Suppl 1): 19-22.